Mirum Pharmaceuticals (MIRM) Total Non-Current Liabilities (2018 - 2026)

Mirum Pharmaceuticals' Total Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $600.2 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 35.45% year-over-year to $600.2 million; the TTM figure through Mar 2026 stood at $600.2 million (up 35.45% YoY), while the FY2025 annual figure was $528.1 million, up 19.32% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $600.2 million, up from $528.1 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $600.2 million in Q1 2026, with the low at $36.3 million in Q1 2022.
• The 5-year median for Total Non-Current Liabilities is $413.1 million (2024), against an average of $355.3 million.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities slumped 68.09% in 2022, then surged 569.02% in 2023.
• Mirum Pharmaceuticals' Total Non-Current Liabilities stood at $206.3 million in 2022, then surged by 91.0% to $394.1 million in 2023, then grew by 12.31% to $442.6 million in 2024, then increased by 19.32% to $528.1 million in 2025, then increased by 13.64% to $600.2 million in 2026.
• Business Quant data shows MIRM's Total Non-Current Liabilities at $600.2 million in Q1 2026, $528.1 million in Q4 2025, and $477.1 million in Q3 2025.